CAR-T cell manufacturing: Major process parameters and next-generation strategies

1Since the first approval by the United States Food and Drug Administration (FDA) in 2017, chimeric antigen receptor (CAR)-T cell therapy has become a major component in the arsenal against B-cell malignancies including leukemia, lymphoma, and multiple myeloma (MM). To date, six products targeting either CD19 or B-cell maturation antigen (BCMA) have been approved in the U.S., with a large number of ongoing trials evaluating additional candidates targeting both hematological malignancies and solid tumors. In addition, CD19 CAR-T cell therapies have recently been applied to the treatment of autoimmune diseases, with early data showing promising outcomes for patients with systemic lupus erythematosus.

2Successful expansion of CAR-T cell therapy to solid tumors and indications beyond cancer is highly dependent on the safety and efficacy of CAR-T cell products. CAR construct design and strategies by which CAR-T cells can be engineered to promote fitness, persistence, and antitumor efficacy have been reviewed in detail in several recent articles. Here, we focus our attention on autologous CAR-T cell manufacturing, which plays a critical role in the clinical impact of CAR-T cell therapy by influencing the phenotype and function of the CAR-T cell products. Although many of the aspects discussed in this review also apply to the manufacturing of allogeneic CAR-T cells, additional considerations exist for the engineering of donor T cells or the differentiation of stem cells into T-cell products, and discussions on these topics can be found in several excellent articles.

3The study of CAR-T cell manufacturing and its impact on therapeutic outcomes is inherently challenging due to the lack of perfectly controlled experiments. In the autologous cell therapy setting, each T-cell product is unique and donor-to-donor variation can be significant, especially in the context of heavily pretreated patients with prior exposure to hematologic toxicity and prior lymphotoxic therapies. Furthermore, manufacturing protocols vary from trial to trial and are often proprietary, precluding facile attribution of differences in clinical outcome to specific differences in manufacturing processes. Nevertheless, accumulating experience in the field has identified phenotypes that are correlated with durable responses to therapy, including a higher proportion of naïve and/or memory cell types, lower frequency of T cells expressing exhaustion markers, lower regulatory T cell (Treg) content, and higher overall proliferative potential. Furthermore, clinical evidence suggests the CAR-T cell product’s phenotype also impacts the toxicity profile experienced by patients after infusion, highlighting the importance of manufacturing processes that can consistently yield cell products with the desirable characteristics.

4The manufacturing processes for several FDA-approved CAR-T cell products have been described in literature with broad similarities as well as unique features (Table 1). The overall process involves isolation of the starting cell population from the leukapheresis product, T-cell activation, genetic modification, ex vivo expansion, final product formulation, and product release testing (Fig. 1). This review aims to provide an overview of how process parameters in each key manufacturing step impact the resulting cell product and discusses next-generation manufacturing strategies with the potential to significantly alter the CAR-T cell therapy landscape in terms of therapeutic efficacy and patient access.

5The choice of starting cell population for CAR-T cell manufacturing is an early decision point with significant impact on the production process as well as the final product. Autologous CAR-T cell manufacturing processes generally begin with mature T cells either in purified form or as part of the peripheral blood mononuclear cell (PBMC) population. Mature T cells differentiate from the naïve (TN) phenotype into stem-cell memory (TSCM), central memory (TCM), effector memory (TEM), effector (TE), and exhausted (TEXH) cells. Furthermore, T cells can be categorized into CD8+ cytotoxic T cells, CD4+ helper T cells, and CD4+ Tregs. Within the helper T cell category, one could further identify subpopulations such as Th1, Th2, Th17, and follicular helper cells. The diversity of T-cell phenotypes renders the choice of starting cell population a major process parameter in CAR-T cell manufacturing. However, biology is not the only factor influencing the choice of starting material as the patient’s clinical history and health status also impose practical constraints on the materials that can be feasibly obtained for cell manufacturing.

6CAR-T cells are activated directly through CAR antigen binding without the need for coreceptor binding to MHC molecules. Therefore, CAR-T cell function does not, in principle, require CD4 and CD8 molecules as coreceptors. Early developmental work on CAR-T cells contemplated the advantage of selective enrichment of CD8+ T cells to maximize cytotoxicity. However, CD4+ helper T cells also play a critical role in promoting CD8+ T cells’ effector function, expansion, and persistence, and it has been shown that the presence of CD4+ T cells in the tumor microenvironment results in increased recruitment, proliferation, and function of CD8+ cytotoxic T cells. Therefore, currently approved CAR-T cell products all contain both CD4+ and CD8+ T cells, although divergent manufacturing approaches are employed.

7Among the CD19-specific CAR-T cell products, tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), and brexucabtagene autoleucel (brexu-cel) all utilize mixed CD4+ and CD8+ T cells. In contrast, lisocabtagene maraleucel (liso-cel) comprises two different cell products—made separately from CD4+ and CD8+ starting cell populations—that are admixed prior to administration. This more complex manufacturing process is motivated by preclinical studies suggesting defined CD4:CD8 ratios may confer superior antitumor efficacy, although clear distinctions in efficacy and safety profiles between liso-cel and other products will require broader and longer-term data collection.

8Cell isolation is commonly achieved through magnetic bead–based cell sorting. A mixture of CD4+ and CD8+ cells can be isolated through the depletion of non-T cells or by positive selection using a combination of CD4− and CD8-binding microbeads. The process of isolating a mixed T-cell population is relatively streamlined and can be accomplished at lower cost compared with parallel manufacturing of separate CD4+ and CD8+ cell cultures, but it precludes the possibility of precisely controlling the CD4:CD8 ratio in the final product. Alternatively, CD4+ and CD8+ T cells can be isolated and cultured separately, allowing for the formulation of a final product with precise CD4:CD8 ratios. However, this approach comes at the cost of increased labor, time, and cost of manufacturing. Furthermore, optimal CD8+ T-cell expansion requires the presence of CD4+ T cells, rendering the manufacturing of isolated CD8+ T cells vulnerable to production failure. A potential solution to this challenge is to isolate CD4+ and CD8+ T cells separately but coculture at defined starting ratios, with the aim of generating a final cell product with approximately the desired ratio of CD4:CD8 T cells. Such a strategy has been shown to overcome the difficulty of CD8+ T-cell expansion, resulting in a product with increased cytotoxic function in mice compared to CD4+ and CD8+ T cells cultured separately. However, such “defined” manufacturing methods cannot completely prevent manufacturing failures. Importantly, the starting CD4:CD8 ratio needed to yield the desired final ratio in the product can vary by donor, thus a precise product profile remains challenging by this approach.

9Beyond CD4:CD8 ratios, the differentiation state of the T-cell product has been shown to correlate with antitumor efficacy profiles. Upon antigen stimulation, T cells undergo clonal expansion and a subset differentiates into TE cells, which have potent cytotoxicity and cytokine production capabilities but are relatively short-lived, in contrast, a subset of activated T cells become memory T cells that are long-lived and quickly activated in response to a secondary antigen challenge. Compared with terminally differentiated TE cells, TN, TSCM, and TCM cells possess greater potential for long-term persistence and produce lower levels of inflammatory cytokines, which could together enable durable anti-tumor response while avoiding severe acute toxicities such as cytokine release syndrome (CRS;;; ). Such findings have supported exploration of manufacturing processes that begin by enriching for naïve and memory T cells, with early evidence suggesting such products can achieve robust efficacy combined with a favorable safety profile.

10The surface expression of CD45RA, CD45RO, CD62L, and CCR7 is commonly used to identify T-cell subtypes, and naïve and memory T cells can be isolated from a leukapheresis product by selecting for CD62L+ cells. However, CD62L+ selection can simultaneously lead to unintended enrichment of CD14+ myeloid cells and CD25+ Tregs that also express CD62L. Myeloid cells have been shown to significantly reduce the efficiency of T-cell activation and subsequent viral transduction, potentially due to phagocytosis of the anti-CD3/CD28 magnetic beads used to activate T cells. Furthermore, the presence of Tregs in the CAR-T product has been reported to correlate with poor antitumor efficacy. These findings suggest that CAR-T products may benefit from the depletion of CD14+ and CD25+ cell types prior to the enrichment of CD62L+ cells, and the use of CD14−/CD25−/CD62L+ cells as the starting material for CAR-T cell manufacturing was evaluated in multiple clinical trials (e.g., NCT02208362 and NCT04007029).

11Unexpectedly, data from one trial (NCT04007029) revealed that CAR-T cell products made from starting populations that were not depleted of CD14+ and CD25+ cells prior to CD62L enrichment had similar levels of activation, transduction, expansion, and final CD3+ purity level compared with products made from CD14/CD25-depleted starting populations. Products made from non-CD14/CD25–depleted cells showed a clear enrichment in CD4+ T cells at the end of cell manufacturing, but no significant difference in therapeutic outcome was noted between cell products made from CD14/CD25-depleted or non-depleted starting cell populations based on the small number of patients in this phase 1 trial. Of note, the cell-manufacturing process used in this particular clinical trial utilized a polymeric nanomatrix T-cell stimulant rather than a magnetic bead–based activating reagent, and the differential phagocytic response displayed by myeloid cells against activating reagents of different sizes and rigidities may have played a key role in the behavior of the resulting cell product. We next discuss the importance of the activation step in the CAR-T cell manufacturing process.

12T-cell activation is critical to the success of the cell-manufacturing process as it directly impacts the efficiency of CAR transgene integration (discussed in the next section) as well as T-cell expansion during ex vivo culture. T-cell activation is most commonly achieved through the stimulation of CD3 and CD28 combined with cytokine support. CD3 signaling (signal 1) triggers T-cell activation while CD28 signaling provides the necessary costimulation (signal 2) to avoid anergy. In addition, cytokine cocktails (signal 3)—most commonly IL-2, IL-7, and/or IL-15—are used to support T-cell expansion. At present, manufacturing protocols typically utilize magnetic beads or colloidal polymeric nanomatrices coated with anti-CD3 and anti-CD28 antibodies to provide signals 1 and 2. Magnetic beads offer solid support that mimics target cells presenting peptide–MHC complexes and costimulatory ligands for T-cell engagement, and anti-CD3/CD28 beads can simultaneously serve as a T-cell isolating agent for magnetism-based cell sorting. However, magnetic beads are prone to engulfment by myeloid cells, thus cell sorting using anti-CD3/CD28 beads poses the risk of enriching for CD14+ cells while reducing the amount of activating reagents available to stimulate T cells. Furthermore, a debeading step through magnetic separation is required to generate a pure CAR-T cell product prior to reinfusion. In contrast, colloidal polymeric nanomatrices appear to be less prone to elimination by myeloid cells and can be removed by simple centrifugation. However, head-to-head comparisons of these reagents have not been reported to enable rigorous comparison of resulting cell products.

13Regardless of format, commercially available activating agents are standardized products applied at a fixed bead:cell ratio or per-volume dilution ratio. More recent developments have explored the possibility of personalized T-cell activation reagents tailored for each individual product based on the patient’s disease type. For example, utilizing mesoporous silica microrods coated with a lipid bilayer, Mooney and colleagues developed APC-mimetic scaffolds that can not only provide anti-CD3 and -CD28 signals but also enable sustained release of IL-2. The density of anti-CD3 and -CD28 antibodies can be precisely tuned to provide the optimal stimulation intensity to maximize T-cell fitness. The implementation of finely tuned, highly personalized reagents would have to be balanced against practical considerations of production throughput and process robustness. Nevertheless, the emergence of “smart” materials that can be adapted to different product requirements could significantly expand the flexibility and quality of manufacturing processes.

14It should be noted that although T-cell activation is an indispensable step in present-day CAR-T cell manufacturing, next-generation manufacturing processes are contemplating the possibility of eliminating T-cell activation. For example, a recent report described the successful transduction of non-activated T cells by lentiviral vectors. Next, we discuss the various methods available for CAR transgene introduction, including both viral and non-viral approaches.

15The method of CAR transgene delivery can significantly impact the level of CAR transgene expression as well as genotoxicity, which in turn influences the safety and efficacy of the resulting CAR-T cell product. In this section, we broadly evaluate both viral and non-viral gene-delivery methods for CAR-T cell manufacturing.

16Currently, all FDA-approved CAR-T cell products use lentiviral or retroviral transduction to achieve CAR transgene integration (; Table 1). Viral transduction benefits from relatively high integration efficiency, and T cells expressing stably integrated CAR constructs have been shown to persist for >10 yr after T-cell infusion. However, virally integrated transgenes lack insertion-site specificity, presenting a theoretical risk of insertional mutagenesis. A genome-wide profiling study compared transgene integration sites in CAR-T cell products made with γ-retroviral vectors versus lentiviral vectors, with results indicating that lentiviral vectors are more likely to integrate in the intron and intergenic regions compared with retroviruses; in contrast, retroviruses have higher frequencies of integration into promoters, untranslated regions, and exon regions, resulting in a greater impact on mRNA transcript levels. It is important to note that there has been no reported instance to date of viral integration resulting in oncogenic transformation of CAR-T cells. On the contrary, a case study reported a patient whose response to CD19 CAR-T cell therapy appeared to correlate with the expansion of a single CAR-T cell clone whose CAR transgene was randomly inserted in the TET2 locus, thereby knocking out the only functional TET2 copy as the patient had a congenital missense mutation in the other TET2 allele. Similarly, clonal expansion of CD22 CAR-T cells with a copy of the provirus integrated in the CBL gene locus was found to expand dramatically prior to eradication of residual disease in a patient with B-cell acute lymphoblastic leukemia (B-ALL; ). Although these cases show that random insertion may serendipitously result in positive therapeutic outcome, the risk of insertion into undesirable loci remains a motivation for exploring alternative transgene-integration strategies that could ensure site specificity.

17Aside from integration-site considerations, viral vectors present another potential risk in the form of replication-competent retroviruses (RCRs) and lentiviruses (RCLs). Accordingly, the FDA requires RCR/RCL detection assays for the viral vectors as well as virally transduced cell products. However, there has been no reported instance of RCR and RCL detected in clinical CAR-T cell products to date, and balancing the cost and potential delays caused by RCR/RCL testing with the practical benefit of such assays remains a topic of active scientific exploration.

18Although viral transduction can in principle achieve high transduction efficiency, achieving consistent levels of transgene integration in patient cell products presents a technical challenge. Indeed, 10% or lower CAR positivity—levels set based on the premise that transduced cells will expand in vivo upon antigen exposure—is not uncommon as a minimum threshold for transduction efficiency in cell products used in clinical trials. To minimize the risk of manufacturing failure due to poor transgene expression, manufacturing protocols can incorporate the use of transduction enhancers such as protamine sulfate, retronectin, and poloxamer. A rate-limiting step in viral transduction is the initial attachment of the viral particle to the cell membrane, a process that can be facilitated by the use of retronectin for retroviral transduction and polycations such as protamine sulfate for lentiviral transduction. Polycations serve as an electrostatic bridge that links the virus to the cell surface. However, protamine sulfate’s toxicity to T cells presents a counterweight to the benefit of increased transduction efficiency. In contrast, retronectin does not lead to T cell toxicity but its use is limited to retroviral vectors. Proprietary transduction enhancers with more favorable toxicity profiles have been developed, although their high costs and proprietary access can present a barrier to widespread usage.

19In addition to the biological properties of virus transduction, practical considerations also influence the use of viruses in CAR-T cell manufacturing. The number of certified facilities capable of producing clinical-grade virus remains limited. Consequently, the time and financial cost required for virus production can present a bottleneck in both investigational drug development and commercial CAR-T cell manufacturing, highlighting the appeal of alternative, non-viral delivery systems that may be more flexible and cost-effective.

20Several different non-viral gene delivery methods have been explored in the context of CAR-T cell manufacturing, including CRISPR/Cas9, transposons, and mRNA transfection. CRISPR/Cas9 has enjoyed widespread adoption as an efficient method for genome modification, and its potential to enhance CAR-T cell therapies has not gone unnoticed. To achieve site-specific gene modification, the Cas9 nuclease is complexed with a single-guide RNA (sgRNA), identifies the target site on genomic DNA via sequence complementarity to the sgRNA, and introduces a double-stranded DNA break. Next, transgene insertion is facilitated through homologous recombination between a DNA template that encodes for the desired transgene (e.g., CAR) and the genomic cut site.

21The ability to specify the transgene-integration site opens up new possibilities in engineering T cells with desired functions. A number of extragenic “safe-harbor” sites have been computationally identified and empirically tested to support the precise genetic modification of T cells for therapeutic functions. In particular, it has been shown that CAR transgenes can be efficiently integrated into the TRAC locus that encodes for the endogenous TCR α chain using an adeno-associated viral vector as the homology-directed repair template. This strategy commandeers the endogenous gene regulatory mechanisms that dynamically control TCR expression levels in response to T-cell activation states, with data suggesting that the resulting CAR-T cells may be more efficacious than virally integrated CAR-T cells. In addition, non-viral CRISPR/Cas9-based gene-editing strategies have also been used to replace the endogenous TCR with tumor-specific TCRs, enabling the development of highly personalized T-cell therapies. As another example, the aforementioned case study involving TET2 mutations has inspired subsequent evaluation of intentional CAR transgene integration into the TET2 site as a means to enhance CAR-T cell proliferation and persistence. Interestingly, results showed that the benefit of TET2 disruption on in vivo antitumor efficacy varied with the specific CAR constructs expressed, echoing similar findings on CAR integration into the TRAC locus and highlighting the non-trivial nature of identifying optimal integration sites for CAR transgenes.

22In addition to facilitating site-specific transgene integration, CRISPR/Cas9 has also been used in combination with viral integration to knock out undesirable endogenous genes while non-site-specifically integrating the transgene encoding for a tumor-targeting receptor. For example, the first FDA-approved clinical trial involving CRISPR/Cas9-edited T cells utilized a manufacturing process that knocked out PD-1 and the endogenous TCR with CRISPR/Cas9 while lentivirally integrating a transgenic TCR targeting NY-ESO-1. Of note, it was observed that the frequency of NY-ESO TCR-expressing cells with mutations in the PDCD1 locus decreased over time after infusion, suggesting that PD-1–edited T cells might lack the ability to form long-term memory. In another phase 1 clinical study, CRISPR/Cas9 was used to knock out PD-1 and the TCR α chain while a mesothelin-targeting CAR was lentivirally integrated. Although both studies showed acceptable safety profiles, neither resulted in dramatic improvements in efficacy, highlighting the need for continued improvement. Furthermore, CRISPR/Cas9-mediated double-stranded DNA break poses a non-trivial risk of unintended genomic changes that require careful analysis and quality control, and a recent study revealed the potential for chromosome loss in Cas9-engineered CAR-T cells. Interestingly, the same study observed that the specific order of operations impacted the frequency of chromosome loss, which can be reduced if the Cas9-mediated double-stranded break is performed before the T cells are activated.

23As an alternative to CRISPR/Cas9, transposons have also been used to achieve stable CAR transgene integration into T-cell products. In particular, piggyBac and Sleeping Beauty (SB) transposon systems have been evaluated in the clinical setting. Transposon systems perform “cut-and-paste” processes in which a transposase binds to terminal inverted repeat sequences flanking a target gene element (i.e., the transposon), excises the transposon through double-stranded DNA break, and reintegrates the transposon into a suitable genomic site (e.g., palindromic sequences comprising AT dinucleotides in the case of SB transposons;; ). Transgene integration by this means is not site specific, and piggyBac transposases have been reported to exhibit preferential insertion into transcriptional start sites similar to retroviruses, again raising the potential risk of insertional mutagenesis. In a phase 1 clinical trial, two patients treated with allogeneic CD19 CAR-T cell products generated with the piggyBac transposon system developed CAR-T cell–derived lymphoma, resulting in one fatality. Post-hoc analysis indicated that the malignant CAR-T cells did not contain transgene insertion into known oncogenic sites but displayed significant copy-number gains and losses of multiple chromosomes as well as transcriptional readthrough from the transgene promoter. Importantly, the products that resulted in malignant transformation had unusually high vector copy numbers (VCN), with one product having a VCN of 25. By comparison, in the absence of product-specific justifications, the FDA-recommended maximum is five copies per transduced cell for virally transduced cell products.

24One strategy to eliminate the risk of oncogenic insertion is to avoid stable integration of the CAR-encoding transgene and instead transiently express the CAR from an mRNA template. In addition to eliminating the risk of genotoxicity, transient CAR expression from mRNA has also been explored as a means to reduce potential toxicity, particularly when the CAR targets an antigen that is also present in healthy tissues. Transgene-encoding mRNA templates are typically delivered into T cells by electroporation, and transgene expression lasts for ∼1 wk, with expression levels declining each day after electroporation. Therefore, the potential safety advantage of transient gene expression must be balanced against the necessarily short-lived nature of the therapy. Clinical evaluations suggest that mRNA-encoded CAR-T cells are safe and can exhibit antitumor efficacy, but the ability to achieve complete and durable tumor control remains an area of investigation.

25Once T cells have been modified to express the CAR transgene, the product must be expanded to a sufficiently large number to meet the required dose for administration. The duration of this expansion period varies across different protocols, but typical processes last 1–2 wk from the time of T-cell activation to the time of cell harvest. The expansion condition is optimized for T-cell growth, with cytokine support such as IL-2, IL-7, and/or IL-15. Although the main purpose of the expansion period is to increase T-cell numbers, it also eliminates non-T cells by exposing them to culture conditions that are suboptimal to other cell types, thus enabling the generation of a highly enriched T-cell product even if the manufacturing process begins with mixed PBMCs. In addition to cytokines, culture supplements such as FBS also play a critical role in supporting T-cell expansion, although defined media compositions that enable more precise formulation and lower risk of zoonotic pathogens are rapidly supplanting components such as FBS. Finally, recent studies have explored the use of various pharmacological supplements to promote desirable T-cell phenotypes and enhance the therapeutic potential of the resulting CAR-T cell product. For example, the tyrosine kinase inhibitor dasatinib has been used in CAR-T cell manufacturing to inhibit CAR tonic signaling (i.e., receptor signaling in the absence of antigen stimulation), thereby preventing premature T-cell exhaustion and increasing CAR-T cell functionality. This strategy was used to produce GD2-targeted CAR-T cells—which are known to strongly tonically signal and exhibit a propensity toward exhaustion—for a phase 1 trial, with early results showing remarkable improvements in multiple patients with H3K27M-mutated diffuse midline gliomas. Since multiple doses of CAR-T cells were administered to each patient enrolled in this trial, definitive conclusions on whether dasatinib prevented exhaustion and/or enabled sustained T-cell function remain elusive. Nevertheless, this example demonstrates the feasibility of pharmacologically modulating the CAR-T cell manufacturing process to generate functional CAR-T cell products for clinical translation.

26Capitalizing upon the groundbreaking success of CAR-T cells in the treatment of hematological malignancies in 2017, over 1,000 active CAR-T cell clinical trials are in progress globally, concentrated in the North American and Eurasian continents. This boom in clinical investigations has refined our understanding of relevant parameters for successful CAR-T cell products. As with any proposed therapy, CAR-T cells seeking clinical evaluation must meet defined product characteristics relating to safety, purity, potency, identity, and stability. All FDA-approved CAR-T cell products measure the bolded product characteristics below using combinations of the following metrics:•Safety: Mycoplasma, sterility, endotoxin, residual viral-agent quantification, viability, and CAR transgene quantification•Purity: T-cell purity, viability, residual reagent quantification, transduction efficiency, and presence of contaminating tumor cells•Potency: Transduction efficacy, viability, CAR expression, cytotoxicity, or cytokine (e.g., IFN-γ) production upon antigen stimulation•Identity: CAR expression, visual appearance, clarity, dose, and viability•Stability: Formulation, shipping, and storage.

27•Safety: Mycoplasma, sterility, endotoxin, residual viral-agent quantification, viability, and CAR transgene quantification

28•Purity: T-cell purity, viability, residual reagent quantification, transduction efficiency, and presence of contaminating tumor cells

29•Potency: Transduction efficacy, viability, CAR expression, cytotoxicity, or cytokine (e.g., IFN-γ) production upon antigen stimulation

30•Identity: CAR expression, visual appearance, clarity, dose, and viability

31•Stability: Formulation, shipping, and storage.

32The FDA has recently drafted standardized expectations for CAR-T cell products. In particular, lot release criteria for early-phase investigational new drug application submissions do not require validated potency assays and specifications, but such assays must be included when generating data in support of the Biologics License Application.

33Based on accumulating data from ongoing clinical trials and real-world experience, additional parameters have also been proposed to propel future development of more reproducible, effective, and safe therapeutics. For instance, given evidence suggesting CAR-T products with less differentiated, more memory-like phenotypes have greater potential to achieve durable tumor clearance, future commercial products may benefit from setting an efficacy characteristic metric that specifies the proportion of favorable T-cell subpopulations within the product. However, altering and tightening product specifications must be guided by rigorous scientific evidence and fundamental biological understandings to avoid triggering unnecessary manufacturing failures that could curtail access to therapy for patients.

34In certain instances of product failure involving non-life-threatening lot release criteria (e.g., dose, transduction efficacy, cytokine production level, or CAR expression), out-of-specification products can be administered to patients upon receiving necessary regulatory approvals. Within expanded-access protocols, patients have received out-of-specification commercial and clinical-trial products and experienced comparable clinical outcomes as patients treated with standard products. Accumulating clinical experience with CAR-T cell products in the real-world setting will be invaluable in understanding which product characteristics truly impact patient safety and therapeutic efficacy, and may serve as a guide for further refinement of regulatory guidance on CAR-T cell product release testing.

35The manufacturing strategies discussed thus far have supported the development of multiple CAR-T cell products to date and enabled the demonstration of CAR-T cell therapies’ potential to overcome advanced malignancies. However, real-world experiences with CAR-T cell therapy after FDA approval have also highlighted the limitations of conventional cell-manufacturing processes, which are low throughput and resource intensive, resulting in limited patient access to potentially life-saving therapies. As of early 2023, 90% of patients with MM experience disease progression and 25% of patients succumb to disease while waitlisted for BCMA-directed CAR-T cell product slots, with waiting periods ranging from 1 to 10 mo before undergoing apheresis. Upon apheresis, the cells must undergo transportation to and from the manufacturing site, ex vivo modification and expansion, and stringent quality-control testing. The majority of patients required bridging therapy to combat further clinical deterioration during cell manufacturing, which could lead to further infusion delays in patients who experience adverse reactions related to bridging.

36Even in the absence of medical complications during the vein-to-vein time, 4–7% of patients are unable to receive their CAR-T cell products as a result of manufacturing failures, with risk factors including reduced fitness of patient T cells following multiple lines of treatment and the lengthy manufacturing process itself. Therapeutic options following unsuccessful product manufacturing include repeating apheresis or transitioning to alternative therapies, though survival outcomes are poor in both cases. Altogether, the multiple sources of delays leading to loss of life underscore the criticality of timely access to CAR-T cell products. Here, we discuss next-generation strategies under development to address key challenges in CAR-T cell manufacturing (Table 2).

37In response to these challenges in CAR-T cell manufacturing, new strategies have been developed to dramatically decrease the duration of cell manufacturing, thereby reducing production costs, probability of manufacturing failures, and vein-to-vein time. These next-generation manufacturing processes can arrive at final-product formulation within as few as 24 h (Fig. 1), offering the possibility of significantly accelerating patient access to therapy. The bulk of the time-saving results from significant shortening of the ex vivo expansion period, thus limiting the fold increase in cell count that could be accomplished. However, the reduced number of ex vivo cell divisions could also result in a less differentiated T-cell population, with greater long-term proliferative potential after infusion. Indeed, early results indicate that products harvested at earlier time points exhibit greater proportions of TCM cells (CD45RO+CD62L+) and TN/TSCM cells (CD45RO−/CCR7+), which have been reported to exhibit therapeutically favorable phenotype and function.

38One example of a CAR-T cell product made with accelerated manufacturing is the CD19-directed YTB323 cells manufactured with the “T-Charge” platform, which requires <2 d in ex vivo culture. YTB323 cells have been reported to exhibit an enrichment of TN and TSCM cells, as well as a more similar CD4:CD8 ratio as that found in the apheresis material, in comparison to the equivalent product produced using the conventional CAR-T cell manufacturing process (tisa-cel; ). Of note, preliminary results from a phase-2 trial indicate that YTB323 can yield comparable efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) as tisa-cel but at a 25-fold lower dose, suggesting the reduced ex vivo culture time may have yielded a functionally superior product. As another example, the BCMA-directed PHE885 cells manufactured with the same T-Charge platform achieved a 98% overall response rate in a phase-1 trial for patients with relapsed/refractory MM. Of note, CAR-T cells were detectible at 6 mo after infusion in 93% (13/14) of patients and at 12 mo in 71% (5/7) of patients, indicating robust in vivo T-cell persistence.

39Another accelerated manufacturing platform, termed FasT CAR-T, has been used to generate “CD19 F-CAR-T” cells for patients with B-ALL, with 92% (23/25) of patients achieving minimum residual disease-negative complete responses. The majority (20/25) of patients in this trial proceeded to undergo allogeneic hematopoietic stem-cell transplantation, and thus the long-term durability of response to CAR-T cell therapy could not be assessed. As the clinical data from multiple trials continue to mature, the relative durability of response induced by CAR-T cell products generated through different manufacturing platforms will be a significant point of interest.

40A theoretical concern associated with the accelerated cell manufacturing process is that CAR-T cells cryopreserved shortly after ex vivo activation may exhibit an overly stimulated phenotype. Furthermore, particularly in the context of hematological malignancies, products from highly abbreviated manufacturing processes have increased probability of containing tumor cells that would otherwise have been depleted during a prolonged ex vivo culture period under conditions optimized for T-cell growth. However, available clinical data suggest that the safety profile of CAR-T cell products manufactured through these shortened protocols remains clinically manageable. Phase 1 study results for YTB323 in the treatment of DLBCL showed 33% (15/45) of patients experienced CRS, with one grade-4 event, and 11% (5/45) experienced immune effector cell-associated neurotoxicity syndrome (ICANS), with two grade-3 events. In patients with B-ALL, CD19 F-CAR-T cells exhibited greater toxicity, tripling the incidence of CRS (96% overall; 24% grade ≥3) and doubling ICANS (28%, all grade ≥3). Twenty-one of 25 patients required interventional corticosteroids during the CRS onset period, though treatment did not ablate peak CAR-T cell expansion. Additional data from ongoing clinical trials will be highly informative in establishing our understanding of the biological differences among CAR-T cell products manufactured through different platforms. Finally, it is important to note that regulatory requirements on product release testing remain applicable to products manufactured with accelerated processes, and the time required for such release testing still needs to be accounted for in estimating the vein-to-vein time.

41Another avenue by which commercial CAR-T cell production may be improved involves the automation of the manufacturing process, which has the potential to reduce production costs, the probability of manufacturing failures attributed to human error, and contamination via touchpoints. In certain jurisdictions (e.g., the United States), some automated systems are considered fully enclosed and allowed to be operated outside facilities that meet Good Manufacturing Practice standards. Furthermore, automation could significantly reduce the number and experience level required for the manufacturing staff. These factors, in turn, support the possibility of on-site manufacturing that provides fresh, non-cryopreserved products for patients. In a phase-1 trial for patients with non-Hodgkin lymphoma, patients were given CD19/CD20 bispecific CAR-T cells that were either administered fresh or thawed from cryopreserved aliquots, with early data showing fresh CAR-T cell products had higher viability (93% fresh versus 63% cryopreserved; ). A follow-up report on the trial confirmed that patients treated with fresh CAR-T cell products experienced substantially higher complete response rates (80% fresh versus 29% cryopreserved) as well as greater CAR-T cell expansion and persistence compared with patients treated with cryopreserved CAR-T cells. Although it remains possible that improvements in cell-cryopreservation procedure could reduce the difference in efficacy observed between fresh and cryopreserved CAR-T cell products, these results highlight the potential advantage of on-site cell manufacturing. However, scaling such a practice to a large number of medical centers while ensuring consistent product quality remains a key challenge. Importantly, several regulatory changes would be required to allow point-of-care CAR-T cell manufacturing, and differences among jurisdictions across the globe represent substantial hurdles in the practical implementation of on-site cell manufacturing. Furthermore, the use of fresh cell products precludes the completion of release testing that requires long incubation periods, necessitating reliance on in-process sample testing as well as contingency clinical management plans for scenarios in which failed sterility or other test results are received after the cell product has already been infused. In addition, the administration of fresh products poses significant logistical challenges as it requires close temporal coordination between cell manufacturing and patient readiness for receiving cell infusion. Finally, the highly standardized nature of automated systems can pose challenges when the optimal process-parameter setting needs to be adjusted on a patient-by-patient basis. For example, cells from different patients could have dramatically different expansion rates, thus the amount of media needed on each day to maintain the proper cell density in the culture could vary widely across manufacturing campaigns. To achieve the optimal outcome, instruments need to be equipped to sense critical parameters and respond accordingly.

42Looking further ahead, the next-next-generation manufacturing process may completely eliminate ex vivo cell manipulation and expansion, and instead produce therapeutic cell populations in vivo. Several preclinical studies have demonstrated the ability to transduce T cells in vivo using lentivirus or adeno-associated virus. Furthermore, lipid nanoparticles (LNPs) and polymeric nanocarriers have been shown to deliver nucleic-acid payloads to T cells in vivo. To achieve T-cell targeting, the viral particles, LNPs, and nanocarriers are typically decorated with a single-chain variable fragment or other binding domains targeted to CD3, CD4, or CD8. However, the specificity for T-cell targeting may not need to be absolute, and one could contemplate the potential advantage of simultaneously generating CAR-T cells, CAR–natural killer cells, and CAR-macrophages. Nevertheless, it remains critical that the transgene is not delivered into malignant cells, as such an integration event could result in CAR proteins masking the target antigen and shielding the tumor cell from detection by CAR-expressing effector cells. Furthermore, off-target gene delivery increases the risk of genotoxicity in the case of viral vectors that can achieve stable transgene integration. In practical terms, specifically targeting the transgene-delivery vehicle to T cells and strategies to facilitate efficient transgene integration without external T-cell activation are likely necessary to generate an effective dose of CAR-T cells that can achieve durable antitumor efficacy. Finally, in-depth pharmacokinetics and safety demonstrations will be needed prior to clinical translation of in vivo CAR-T cell manufacturing platforms. Despite the many hurdles that remain, the ability to bypass ex vivo cell manufacturing has the potential to significantly reduce cost and increase access to CAR-T cell therapy for patients in need of this treatment option.

43CAR-T cell therapy has become an increasingly important treatment option for hematological malignancies, and clinical trials continue to expand CAR-T cell therapy’s application to the treatment of solid tumors and autoimmune diseases. Consequently, CAR-T cell manufacturing processes that can efficiently and reliably produce high-quality cell products have become essential for supporting timely, safe, and efficacious patient care. Accumulating clinical experience, real-world manufacturing data collection, advancements in automated system engineering, and fundamental understanding of T-cell biology all play critical roles in the continual improvement of autologous CAR-T cell manufacturing processes. Furthermore, the rapidly evolving landscape of allogeneic cell therapy involving additional immune effector cell types as well as T cells generated from stem-cell populations will continue to be a source of both intriguing scientific questions and practical engineering challenges in the coming years.